These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 18953436)

  • 1. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
    Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
    Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
    Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
    Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
    Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 is a direct transcriptional target of MYCN in neuroblastoma.
    Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA
    Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
    Yogev O; Barker K; Sikka A; Almeida GS; Hallsworth A; Smith LM; Jamin Y; Ruddle R; Koers A; Webber HT; Raynaud FI; Popov S; Jones C; Petrie K; Robinson SP; Keun HC; Chesler L
    Cancer Res; 2016 May; 76(10):3025-35. PubMed ID: 27197232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma.
    Liontas A; Yeger H
    Anticancer Res; 2004; 24(2B):987-98. PubMed ID: 15161054
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Yogev O; Almeida GS; Barker KT; George SL; Kwok C; Campbell J; Zarowiecki M; Kleftogiannis D; Smith LM; Hallsworth A; Berry P; Möcklinghoff T; Webber HT; Danielson LS; Buttery B; Calton EA; da Costa BM; Poon E; Jamin Y; Lise S; Veal GJ; Sebire N; Robinson SP; Anderson J; Chesler L
    Cancer Res; 2019 Oct; 79(20):5382-5393. PubMed ID: 31405846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
    Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
    Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis.
    Slack A; Lozano G; Shohet JM
    Cancer Lett; 2005 Oct; 228(1-2):21-7. PubMed ID: 15927364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
    Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
    Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines.
    Ikegaki N; Hicks SL; Regan PL; Jacobs J; Jumbo AS; Leonhardt P; Rappaport EF; Tang XX
    Int J Oncol; 2014 Jan; 44(1):35-43. PubMed ID: 24173829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
    Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
    Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
    Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G
    PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
    Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
    Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
    Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.
    Swarbrick A; Woods SL; Shaw A; Balakrishnan A; Phua Y; Nguyen A; Chanthery Y; Lim L; Ashton LJ; Judson RL; Huskey N; Blelloch R; Haber M; Norris MD; Lengyel P; Hackett CS; Preiss T; Chetcuti A; Sullivan CS; Marcusson EG; Weiss W; L'Etoile N; Goga A
    Nat Med; 2010 Oct; 16(10):1134-40. PubMed ID: 20871609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J; Gu L; Zhang H; Zhou M
    Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.